Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 5/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylformamide SCHEMBL27886458 | 0.87 | ATR (0.38) | ATRPLAUGRM5ALDH1A1KDM4E | |
| SCHEMBL14471555 | 0.83 | PDPK1 (0.45) | ATRPLAUGRM5ALDH1A1KDM4E | |
| SCHEMBL28150098 | 0.83 | ATR (0.42) | ATRPLAUGRM5ALDH1A1KDM4E | |
| SCHEMBL410727 | 0.83 | ATR (0.58) | ATRGRM5ALDH1A1KDM4EGABRP | |
| SCHEMBL30522209 | 0.81 | PLAU (0.59) | PLAUALDH1A1KDM4EAKR1B1PTGS1 | |
| SCHEMBL17501714 | 0.81 | AKR1B1 (0.49) | PLAUALDH1A1KDM4EAKR1B1PTGS1 | |
| SCHEMBL507389 | 0.81 | PLAU (0.59) | PLAUALDH1A1KDM4EAKR1B1PTGS1 | |
| SCHEMBL1674128 | 0.78 | GRM5 (0.42) | PLAUGRM5ALDH1A1KDM4EAKR1B1 | |
| SCHEMBL21195742 | 0.78 | KMT2A (0.40) | ATRGRM5ALDH1A1KDM4EGABRP | |
| SCHEMBL3632923 | 0.78 | MEN1 (0.43) | PLAUGRM5ALDH1A1AKR1B1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106866553-A | A kind of synthetic method of Favipiravir | 中南大学 | 2017-06-20 | — | — | CN | claimed |
| CN-104496917-B | A kind of synthetic method of Favipiravir | 南京华威医药科技开发有限公司 | 2017-06-20 | — | — | CN | claimed |
| EP-3466929-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| CN-107226794-A | A kind of synthetic method of Favipiravir | 郑州大学 | 2017-10-03 | — | — | CN | disclosed |
| CN-104496917-B | A kind of synthetic method of Favipiravir | 南京华威医药科技开发有限公司 | 2017-06-20 | — | — | CN | disclosed |
| CN-106866553-A | A kind of synthetic method of Favipiravir | 中南大学 | 2017-06-20 | — | — | CN | disclosed |
| US-9546165-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546165-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-11-17 | — | — | US | disclosed |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-11-17 | — | — | US | disclosed |
| EP-2485731-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-05-11 | — | — | EP | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | ATR 1624/4885PLAU 4002/4885GRM5 3566/4885 |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | PDK1, PDK2, PDK3 | ATR 1624/4885PLAU 4002/4885GRM5 3566/4885 |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | ATR 1624/4885PLAU 4002/4885GRM5 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.